FGF-1 vs Leuphasyl

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Tetrapeptide that mimics enkephalin to modulate facial muscle contraction; competes with enkephalin for opioid receptor sites in neuromuscular junctions; reduces repetitive muscle micro-contractions

Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu-OH) designed as an enkephalin receptor mimic for topical cosmetic applications, formulated as a claimed anti-wrinkle active ingredient based on the theoretical premise that modulation of enkephalin receptor activity at facial neuromuscular junctions could attenuate dynamic muscle contraction and reduce the appearance of expression lines. The proposed mechanism involves enkephalin receptor interaction to attenuate acetylcholine release or signal transmission at the dermal-epidermal neuromuscular interface, conceptually analogous to botulinum toxin in mechanism but operating at significantly lower potency through a distinct receptor pathway; this theoretical framework draws on the established pharmacology of endogenous enkephalins at opioid and related receptors. No clinical trials, controlled in vivo studies, human safety data, or animal efficacy studies for leuphasyl as a distinct compound are indexed in PubMed; the compound appears exclusively in cosmetic ingredient databases and product formulation literature, with no peer-reviewed evidence base in any indexed scientific journal. Leuphasyl has no FDA approval, no drug regulatory status, and no published clinical evidence in any jurisdiction; it is a cosmetic peptide ingredient marketed on a theoretical mechanism, and any claims of efficacy in reducing wrinkles or expression lines are unsupported by independently published clinical or preclinical data.